Jessica Donington, MD, MSCR

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the sensitivity and specificity of Rapid Lung NGS for biomarker testing in NSCLC.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the utility of Rapid Lung NGS for biomarker testing in NSCLC.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on when to conduct biomarker testing in NSCLC.

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.

Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.

A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.

A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.

Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.

Jessica Donington, MD, MSCR, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer.

Jessica Donington, MD, MSCR, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer. 

Jessica Donington, MD, MSCR, discusses the effectiveness of neoadjuvant immunotherapy and how it compares with neoadjuvant chemotherapy in patients with lung cancer.